Clinical performance of [68Ga]Ga-DOTA-FAPI-04 PET/CT in detecting recurrent disease in medullary thyroid carcinoma: a comparative analysis with [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT, alongside identification of suitable candidates for targeted radionuclide therapy
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-026-08031-w ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Shyam Kumar Ravada und 5 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, 400 012, Mumbai, India. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Thyroid Neoplasms, Fluorodeoxyglucose F18, Organometallic Compounds. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
AIM: To evaluate and compare the diagnostic performance of [68Ga]Ga-DOTA-FAPI-04 with [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT for detecting recurrent disease in patients with medullary thyroid carcinoma (MTC) and additionally evaluate their role for prognostication and theranostics in management of MTC. METHODS: In this prospective single-centre study, 56 patients with suspected recurrent MTC underwent [68Ga]Ga-DOTA-Fibroblast activation protein inhibitor (FAPI)-04, [18F]F-FDG, and [68Ga]Ga-DOTATATE PET/CT. The primary endpoint was patient-based diagnostic accuracy for recurrent disease. Secondary endpoints included lesion-based detection rates across pre-defined anatomical regions, correlation with biochemical and clinicopathological parameters, prognostic assessment for progression-free survival, and a novel exploratory FAPI-SSTR Theranostic (FAST) score was developed to guide personalized radiopharmaceutical therapy (RPT). RESULTS: [68Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated higher sensitivity 95.92% and accuracy 94.64% compared to [18F]F-FDG-PET/CT (sensitivity: 89.80%, accuracy: 89.29%) and [68Ga]Ga-DOTATATE (sensitivity: 77.55%, accuracy: 76.79%) on patient-based analysis for detecting recurrent disease. [68Ga]Ga-DOTA-FAPI-04 was showed high detection rates for disease recurrence in mediastinal nodal (91.9%), liver (91.7%), and skeletal (86.5%) metastases.[68Ga]Ga-DOTA-FAPI-04 uptake was associated with a modestly shorter mean progression-free survival and altered clinical management in 35.7% of total patients. Additionally, the pre-defined exploratory FAST scoring system stratified 34 patients (60.7%) for [177Lu]Lu-FAPI-RPT, 8 (14.3%) for [177Lu]Lu-DOTATATE PRRT, and 9 (16.1%) for either or combined RPT. CONCLUSION: [68Ga]Ga-DOTA-FAPI-04 PET/CT showed higher diagnostic accuracy for the identification of recurrent MTC over standard [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT, with higher regional detection rates for liver and osteoblastic skeletal metastases. Furthermore, while the exploratory FAST score provides a framework for patient stratification and personalizing targeted theranostic strategies, it requires future validation through larger multicentre trials prior to clinical adoption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, 400 012, Mumbai, India.
- Homi Bhabha National Institute, Mumbai, India.
- Department of Surgical Oncology, Tata Memorial Centre, Parel, Mumbai, 400 012, India.
- Department of Medical Oncology, Tata Memorial Centre, Parel, Mumbai, 400 012, India.
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, 400 012, Mumbai, India. drsanb@yahoo.com.
- Homi Bhabha National Institute, Mumbai, India. drsanb@yahoo.com.
Zitieren
APA
Ravada, S. K., Parghane, R. V., Deshmukh, A., Shah, M., Pantvaidya, G., & Basu, S. (2026). Clinical performance of [68Ga]Ga-DOTA-FAPI-04 PET/CT in detecting recurrent disease in medullary thyroid carcinoma: a comparative analysis with [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT, alongside identification of suitable candidates for targeted radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08031-w
Vancouver
Ravada SK, Parghane RV, Deshmukh A, Shah M, Pantvaidya G, Basu S. Clinical performance of [68Ga]Ga-DOTA-FAPI-04 PET/CT in detecting recurrent disease in medullary thyroid carcinoma: a comparative analysis with [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT, alongside identification of suitable candidates for targeted radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08031-w
BibTeX
@article{Ravada2026,
author = {Ravada, Shyam Kumar and Parghane, Rahul Vithalrao and Deshmukh, Anuja and Shah, Minit and Pantvaidya, Gouri and Basu, Sandip},
title = {Clinical performance of [68Ga]Ga-DOTA-FAPI-04 PET/CT in detecting recurrent disease in medullary thyroid carcinoma: a comparative analysis with [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT, alongside identification of suitable candidates for targeted radionuclide therapy},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-026-08031-w}
}
EUVIMED